0.27
-0.0039(-1.43%)
Currency In USD
| Previous Close | 0.27 |
| Open | 0.25 |
| Day High | 0.28 |
| Day Low | 0.24 |
| 52-Week High | 1.22 |
| 52-Week Low | 0.15 |
| Volume | 593,830 |
| Average Volume | 9.7M |
| Market Cap | 15.19M |
| PE | -0.23 |
| EPS | -1.15 |
| Moving Average 50 Days | 0.31 |
| Moving Average 200 Days | 0.28 |
| Change | -0 |
If you invested $1000 in Processa Pharmaceuticals, Inc. (PCSA) 10 years ago, it would be worth $5.8 as of December 14, 2025 at a share price of $0.268. Whereas If you bought $1000 worth of Processa Pharmaceuticals, Inc. (PCSA) shares 5 years ago, it would be worth $1.68 as of December 14, 2025 at a share price of $0.268.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Processa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 PCS499 Study in FSGS at ASN Kidney Week 2025
GlobeNewswire Inc.
Nov 05, 2025 2:15 PM GMT
VERO BEACH, Fla., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies and innovative treatments for rare diseases, today annou
Processa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury Strategies
GlobeNewswire Inc.
Aug 07, 2025 12:30 PM GMT
VERO BEACH, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies for cancer patients, today announced that it has secured
Processa Pharmaceuticals Provides Portfolio and Business Update
GlobeNewswire Inc.
Jul 01, 2025 1:00 PM GMT
Signed binding term sheet granting Intact Therapeutics an exclusive option to license PCS12852Continue enrolling patients in Phase 2 study of PCS6422Strengthened balance sheet with $7M capital infusion VERO BEACH, Fla., July 01, 2025 (GLOBE NEWSWIR